Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596183 | 0.99 | HTR6 (0.69) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL5231993 | 0.90 | HTR6 (0.82) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL5233760 | 0.88 | HTR6 (0.85) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3585571 | 0.81 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5232161 | 0.80 | HTR6 (0.53) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL5230841 | 0.80 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL946875 | 0.80 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL947647 | 0.79 | HTR6 (0.74) | HTR6CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL946247 | 0.79 | HTR6 (0.98) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL5227430 | 0.78 | HTR6 (0.53) | HTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649097-B2 | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| EP-1523486-B1 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-11-07 | — | — | EP | disclosed |
| US-20050203154-A1 | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
| EP-1523486-A2 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004000849-A2 | TETRACYCLIC ARYLSULFONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203154-A1 | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | HTR6 7/4885CYP3A4 139/4885CYP2D6 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.